Last reviewed · How we verify
Visipaque 270 (IODIXANOL)
Visipaque 270 works by increasing the density of fluids in the body, making them visible on X-ray images.
Visipaque 270 (iodixanol) is a radiographic contrast agent developed by GE Healthcare, currently owned by the same company. It is a small molecule drug used to enhance the visibility of internal structures during medical imaging procedures. Visipaque 270 is off-patent and has a generic manufacturer. It has a half-life of 2.1 hours and was FDA-approved in 1996. The exact target of Visipaque 270 is unknown.
At a glance
| Generic name | IODIXANOL |
|---|---|
| Sponsor | GE HealthCare |
| Drug class | Radiographic Contrast Agent |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
| First approval | 1996 |
Mechanism of action
Intravascular injection of iodixanol opacifies vessels in the path of flow of the contrast agent, permitting visualization of internal structures.In imaging of the body, iodinated contrast agents diffuse from the vascular into the extravascular space. In normal brain with an intact blood-brain barrier, contrast does not diffuse into the extravascular space. In patients with disrupted blood-brain barrier, contrast agent accumulates in the interstitial space in the region of disruption.
Approved indications
Boxed warnings
- WARNING: NOT FOR INTRATHECAL USE Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyolysis, hyperthermia, and brain edema [see Contraindications ( 4 ) and Adverse Reactions ( 5.1 )] . WARNING: NOT FOR INTRATHECAL USE See full prescribing information for complete boxed warning Inadvertent intrathecal administration may cause death, convulsions/seizures, cerebral hemorrhage,
Common side effects
- Pruritus
- Contrast media reaction
- Urticaria
- Erythema
- Acute generalised exanthematous pustulosis
- Rash
- Acute kidney injury
- Anaphylactic reaction
- Contrast encephalopathy
- Contrast media allergy
- Eosinophilia
- Anaphylactoid shock
Key clinical trials
- Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis (NA)
- Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma (NA)
- Intra-discal Steroid Injection for MODIC I Discopathy (PHASE4)
- Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material (PHASE4)
- Effect of Evolocumab on Coronary Atherosclerosis (PHASE3)
- Preoperative Embolization of Hypervascular Head and Neck Tumors to Improve Surgical Outcomes (PHASE1)
- Correlation Between Computer Tomography Angiography and D-Dimer Level for the Diagnosis of Pulmonary Embolism
- Pediatric Risk of Hypothyroidism With Iodinated Contrast Media (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Visipaque 270 CI brief — competitive landscape report
- Visipaque 270 updates RSS · CI watch RSS
- GE HealthCare portfolio CI